Efficiency and Safety of Brentuximab Vedotine as a Salvage Treatment Before Autologous Stem Cell Transplantation in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma: Retrospective Study
The BV as a salvage treatment showed quite high efficiency. Despite a worse clinical characteristic of the BV group, there were no significant differences in the outcomes of the auto-HCT with respect to the salvage regimen (BV versus sCT) used before auto-HCT. Our results suggest that BV before auto-HCT in patients refractory to standard 2nd line treatment equalizes their prognosis to the patient sensitive to standard CT with the same tolerance and toxicity.
Authors
- Jan Maciej Zaucha (ORCID: https://orcid.org/0000-0002-0986-8936)
- Iryna Kriachok (ORCID: https://orcid.org/0000-0002-8141-0735)
- N. Shokun (ORCID: https://orcid.org/0009-0007-4294-2492)
- K. Filonenko (ORCID: https://orcid.org/0000-0002-0725-3110)
- Arina Martynchyk (ORCID: https://orcid.org/0009-0009-3094-8867)
- Yevhen Kushchevyi
- Yana Stepanishyna (ORCID: https://orcid.org/0000-0002-7884-193X)
Institutions
- Institut Jules Bordet (BE)
- Essen University Hospital (DE)
- National Cancer Institute (UA)
- Olivia Newton-John Cancer Wellness & Research Centre (AU)
- West German Heart and Vascular Center Essen (DE)
- Gdańsk Medical University (PL)
Publication Details
- Journal
- Advances in Hematology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1155/ah/3573471
- Primary Topic
- CNS Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00